Catalent Appoints New Leadership Team

On Nov. 19, 2019, Catalent announced the appointment of Mike Grippo to the position of senior vice president, Strategy and Corporate Development. In this newly created role, Grippo will be responsible for identifying and evaluating organic and inorganic growth opportunities across Catalent that will drive long-term shareholder value. He will report to John Chiminski, Catalent’s chair and CEO.

Grippo joined Catalent as vice president of Corporate Development in 2016. In his new role, he will oversee the strategy and corporate development functions of the company as well as Catalent’s scientific team.

In addition to the new appointment, the company has also named Julien Meissonnier vice president and chief scientific officer, who will report to Grippo. In this new role, Meissonnier will join the executive leadership team and will lead Catalent’s new product development and technology innovation programs. Meissonnier will also head up the company’s scientific community and customer advisory partnerships to help improve formulation and adoption of drug-delivery technologies. He will continue to co-chair the Catalent Applied Drug Delivery Institute to leverage emerging new therapeutic modalities.

“Since our IPO in 2014, we have completed seven acquisitions and are expected to close the acquisition of an oral dose and biologics facility in Italy, from Bristol-Myers Squibb, before the end of the calendar year,” commented Chiminski in a company press release. “The decisions to make strategic investments in areas such as biologics, gene therapy, and spray drying have been driven in large part by the work of our Corporate Development team, led by Mike Grippo in partnership with key leaders across the business.”

“During his long career with Catalent, Julien has been instrumental in driving excellence across the R&D community, notably through the launch of the Scientific Resource Center serving the business’s team of approximately 2400 scientists and technicians. He will promote open innovation within the organization, and we welcome both to the executive leadership team,” Chiminski added.

Prior to joining Catalent, Grippo was vice president of Corporate Development for Murray Hill, NJ-based CR Bard, now branded simply as Bard, and a developer, manufacturer, and marketer of medical technologies. Prior to Bard, he held a similar leadership role with Hill-Rom Holdings. Earlier in his career he also held positions with SG Cowen and UBS Securities.

Before Meissonnier’s appointment as vice president and chief scientific officer, he previously held the position of vice president, Science and Technology, and before that led Catalent’s European softgel R&D team.

Source: Catalent